CVRx Valuation Multiples

CVRx Overview

About CVRx

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Founded

2000

HQ

Employees

223

Website

cvrx.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $59M

EBITDA: ($44M)

EV

$190M

Valuation Multiples

Multiples.vc

Start free trial

CVRx Financials

CVRx reported last 12-month revenue of $59M and negative EBITDA of ($44M).

In the same LTM period, CVRx generated $50M in gross profit, ($44M) in EBITDA losses, and had net loss of ($54M).

CVRx P&L

In the most recent fiscal year, CVRx reported revenue of $57M and EBITDA of ($44M).

CVRx expects next 12-month revenue of XXX and NTM EBITDA of XXX

CVRx Stock Performance

CVRx has current market cap of $215M, and enterprise value of $190M.

CVRx's stock price is $8.17.

CVRx Valuation Multiples

CVRx trades at 3.2x EV/Revenue multiple, and (4.3x) EV/EBITDA.

CVRx Financial Valuation Multiples

As of April 5, 2026, CVRx has market cap of $215M and EV of $190M.

Equity research analysts estimate CVRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CVRx has a P/E ratio of (4.0x).

CVRx Margins & Growth Rates

CVRx's revenue in the last 12 month grew by 16%.

CVRx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

CVRx's rule of 40 is (52%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CVRx's rule of X is (31%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

CVRx Public Comps

See public comps and valuation multiples for other Medical Devices comps.

CVRx M&A Activity

CVRx acquired XXX companies to date.

Last acquisition by CVRx was on XXXXXXXX, XXXXX. CVRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

CVRx Investment Activity

CVRx invested in XXX companies to date.

CVRx made its latest investment on XXXXXXXX, XXXXX. CVRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).